MX395719B - Composiciones y métodos para el uso de ésteres de forbol. - Google Patents

Composiciones y métodos para el uso de ésteres de forbol.

Info

Publication number
MX395719B
MX395719B MX2018000468A MX2018000468A MX395719B MX 395719 B MX395719 B MX 395719B MX 2018000468 A MX2018000468 A MX 2018000468A MX 2018000468 A MX2018000468 A MX 2018000468A MX 395719 B MX395719 B MX 395719B
Authority
MX
Mexico
Prior art keywords
disease
methods
conditions
chronic
compositions
Prior art date
Application number
MX2018000468A
Other languages
English (en)
Spanish (es)
Inventor
Hung-Fong Chen
HAN Zeng TAO
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of MX395719B publication Critical patent/MX395719B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
MX2018000468A 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol. MX395719B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261588165P 2012-01-18 2012-01-18
US201261588167P 2012-01-18 2012-01-18
US201261588162P 2012-01-18 2012-01-18
PCT/US2013/022324 WO2013110006A2 (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters

Publications (1)

Publication Number Publication Date
MX395719B true MX395719B (es) 2025-03-25

Family

ID=48799818

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018000468A MX395719B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol.
MX2014008776A MX370146B (es) 2012-01-18 2013-01-18 Composiciones y métodos para uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2019011333A MX389510B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2014008773A MX373291B (es) 2012-01-18 2013-01-18 Composiciones y metodos para el uso de ésteres de forbol

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2014008776A MX370146B (es) 2012-01-18 2013-01-18 Composiciones y métodos para uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2019011333A MX389510B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2014008773A MX373291B (es) 2012-01-18 2013-01-18 Composiciones y metodos para el uso de ésteres de forbol

Country Status (18)

Country Link
US (1) US20170096386A1 (enExample)
EP (2) EP2804669B1 (enExample)
JP (5) JP6336914B2 (enExample)
KR (4) KR20200105731A (enExample)
CN (4) CN104168957A (enExample)
AU (7) AU2013287280B2 (enExample)
BR (2) BR112014017716A8 (enExample)
CA (3) CA2861459C (enExample)
IL (2) IL233676A0 (enExample)
MX (4) MX395719B (enExample)
MY (5) MY177300A (enExample)
NZ (4) NZ628296A (enExample)
PH (10) PH12014501656B1 (enExample)
RU (3) RU2018108884A (enExample)
SG (12) SG10201912653PA (enExample)
TW (7) TW201350111A (enExample)
WO (2) WO2013110006A2 (enExample)
ZA (3) ZA201405564B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
PT2368555T (pt) 2007-01-31 2016-07-25 Biosuccess Biotech Company Composições e métodos de utilização de ésteres de forbol
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
BR112014017716A8 (pt) * 2012-01-18 2021-03-02 Biosuccess Biotech Co Ltd composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
EP3131635A4 (en) * 2014-04-16 2017-10-11 Northern Sydney Local Health District Compositions and methods for the treatment or prevention of neurodegenerative disorders
AU2015314979A1 (en) 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by prostratin
MA40904A (fr) 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
KR101721068B1 (ko) * 2015-01-30 2017-03-29 고려대학교 산학협력단 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
KR20160107426A (ko) 2015-03-04 2016-09-19 임세영 구두 굽 및 그 제조방법
KR101710674B1 (ko) * 2015-07-22 2017-02-27 가톨릭대학교 산학협력단 Epo 수용체 및 pkc 동시 표적물질을 유효성분으로 포함하는 빈혈의 예방 또는 치료용 약학 조성물 및 이의 용도
CN106420687A (zh) * 2016-10-11 2017-02-22 孙君重 防护肠辐射损伤的方法及tpa的用途
US20220016073A1 (en) 2017-11-15 2022-01-20 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
KR102059160B1 (ko) * 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
CN108689851B (zh) * 2018-05-28 2020-04-17 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
AU2020352641B2 (en) * 2019-09-24 2026-08-06 K-Gen Therapeutics, Inc. Diterpenoid compounds that act on protein kinase C (PKC)
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
KR102541582B1 (ko) * 2020-10-29 2023-06-12 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
CN112715542A (zh) * 2021-01-20 2021-04-30 沈阳农业大学 巴豆烷二萜类化合物的制备方法及其在制备杀线虫的杀虫剂中的应用
CN116159126A (zh) * 2022-12-31 2023-05-26 山东大学齐鲁医院 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375308A (en) 1942-08-21 1945-05-08 Ibm Method of making stencil cards
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US20070009529A1 (en) * 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
PT2368555T (pt) * 2007-01-31 2016-07-25 Biosuccess Biotech Company Composições e métodos de utilização de ésteres de forbol
WO2009151496A2 (en) * 2008-03-26 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
CA2744388A1 (en) * 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
RU2426535C2 (ru) * 2009-05-15 2011-08-20 Маргарита Алексеевна Морозова Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
US8575216B2 (en) * 2009-08-04 2013-11-05 Rutgers, The State University Of New Jersey Method of treatment for acute myelogenous leukemia
KR101144327B1 (ko) * 2010-04-02 2012-05-11 한국과학기술연구원 Ｐｋｃ 작용 활성제를 유효성분으로 함유하는 압상스 간질의 예방 및 치료용 조성물
BR112014017716A8 (pt) * 2012-01-18 2021-03-02 Biosuccess Biotech Co Ltd composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol

Also Published As

Publication number Publication date
BR112014017650A2 (pt) 2021-06-08
HK1204447A1 (en) 2015-11-20
CA3077480C (en) 2023-03-14
PH12020550764A1 (en) 2021-08-16
MX373291B (es) 2020-05-06
AU2020200954A1 (en) 2020-02-27
PH12020550768A1 (en) 2021-08-16
AU2019210621A1 (en) 2019-08-22
RU2014133517A (ru) 2016-03-10
TW201804991A (zh) 2018-02-16
KR20140117564A (ko) 2014-10-07
NZ628294A (en) 2017-11-24
SG10201912667QA (en) 2020-02-27
TW201934118A (zh) 2019-09-01
PH12020550765A1 (en) 2021-12-13
SG10201912677PA (en) 2020-02-27
MY176593A (en) 2020-08-18
HK1204461A1 (en) 2015-11-20
SG10201912660UA (en) 2020-02-27
CA2861459C (en) 2020-08-25
MX389510B (es) 2025-03-20
TWI817022B (zh) 2023-10-01
SG10201912676RA (en) 2020-02-27
PH12020550755A1 (en) 2021-07-26
EP2804669A4 (en) 2015-07-22
KR102102640B1 (ko) 2020-06-01
RU2014133516A (ru) 2016-03-10
EP2804669A1 (en) 2014-11-26
IL233676A0 (en) 2014-08-31
AU2013287280B2 (en) 2016-06-30
AU2013287280A1 (en) 2014-08-14
BR112014017716A8 (pt) 2021-03-02
MY199269A (en) 2023-10-24
AU2016234887A1 (en) 2016-10-20
KR20200105731A (ko) 2020-09-08
JP6835778B2 (ja) 2021-02-24
CN104168957A (zh) 2014-11-26
JP2015513315A (ja) 2015-05-07
PH12014501656B1 (en) 2022-07-29
NZ727304A (en) 2018-08-31
SG10201912642RA (en) 2020-02-27
PH12020550759A1 (en) 2021-07-26
JP2018203754A (ja) 2018-12-27
AU2016203714B2 (en) 2018-01-04
MY173042A (en) 2019-12-20
MX370146B (es) 2019-12-03
WO2014011209A1 (en) 2014-01-16
RU2018108884A3 (enExample) 2021-07-01
JP6336914B2 (ja) 2018-06-06
TW202118485A (zh) 2021-05-16
CN104507466A (zh) 2015-04-08
JP2018109014A (ja) 2018-07-12
AU2020200954B2 (en) 2021-11-11
SG11201404212YA (en) 2014-10-30
CA2861459A1 (en) 2013-07-25
TW201817421A (zh) 2018-05-16
RU2018108884A (ru) 2019-02-26
RU2659684C2 (ru) 2018-07-03
AU2016234887B2 (en) 2018-10-04
ZA201508059B (en) 2016-12-21
AU2017276345A1 (en) 2018-01-18
RU2017140059A (ru) 2019-02-12
KR20190129073A (ko) 2019-11-19
CN108969514A (zh) 2018-12-11
EP2804601A4 (en) 2016-07-06
SG10201912649XA (en) 2020-02-27
AU2019210621B2 (en) 2020-01-02
SG10201912653PA (en) 2020-02-27
JP2021073288A (ja) 2021-05-13
IL233674B (en) 2021-03-25
MX2014008773A (es) 2015-04-10
NZ749356A (en) 2021-02-26
EP2804669B1 (en) 2023-03-29
WO2013110006A3 (en) 2015-02-05
TWI802707B (zh) 2023-05-21
CN110025609A (zh) 2019-07-19
JP6463969B2 (ja) 2019-02-06
TWI666015B (zh) 2019-07-21
TW201350110A (zh) 2013-12-16
EP2804601A2 (en) 2014-11-26
JP6715871B2 (ja) 2020-07-01
TWI664964B (zh) 2019-07-11
TWI902001B (zh) 2025-10-21
CA3077480A1 (en) 2013-07-25
RU2017140059A3 (enExample) 2021-07-06
BR112014017650A8 (pt) 2017-07-11
NZ628296A (en) 2017-02-24
AU2013209524A1 (en) 2014-08-14
MY177300A (en) 2020-09-11
MY192285A (en) 2022-08-17
PH12020550762A1 (en) 2021-08-16
PH12020550752A1 (en) 2021-07-26
AU2016203714A1 (en) 2016-06-23
ZA201405564B (en) 2016-02-24
PH12014501656A1 (en) 2014-10-13
CA2862301C (en) 2020-10-20
PH12014501661A1 (en) 2014-10-20
TW201350111A (zh) 2013-12-16
SG10201912674SA (en) 2020-03-30
BR112014017650B1 (pt) 2023-05-02
EP2804601B1 (en) 2025-04-02
SG10201912629UA (en) 2020-02-27
KR20140129000A (ko) 2014-11-06
CA2862301A1 (en) 2014-01-16
MX2014008776A (es) 2015-08-20
JP2015504096A (ja) 2015-02-05
SG11201404211PA (en) 2014-09-26
WO2013110006A2 (en) 2013-07-25
ZA201505443B (en) 2020-02-26
TW202425963A (zh) 2024-07-01
NZ726666A (en) 2019-03-29
SG10201902370QA (en) 2019-04-29
MX2019011333A (es) 2019-12-19
KR102102677B1 (ko) 2020-04-22
PH12020550760A1 (en) 2021-12-13
RU2650963C2 (ru) 2018-04-18
IL233674A0 (en) 2014-08-31
US20170096386A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
PH12020550765A1 (en) Compositions and methods of use of phorbol esters
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112015021888A2 (pt) inibidores de dna-ik
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CA2871471C (en) Dna-pk inhibitors
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
MX2016006336A (es) Compuestos pirazolopirimidina.
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112014032990A2 (pt) seringa
MX391724B (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
BR112013033309A8 (pt) uso de um agonista de rary; uso de um agonista de rary e um sulfatídeo ou análogo de sulfatídeo sintético; uso de um sulfatídeo ou análogo de sulfatídeo sintético; e método in vitro para inibição de ativação de células nkt tipo i
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CO6400226A2 (es) Micrólido anti-inflamatorio
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
WO2016196393A3 (en) Autophagy-inhibiting compounds and uses thereof
AR095353A1 (es) Compuesto
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
OKUYAMA I Look Forward to the Days of Discovering New Findings
TH46833S1 (th) ยางเร่งการตกตะกอน
TH121846S (th) ยางเร่งการตกตะกอน